Physician profile
Nadine Becker
NPI 1962564021
$3,876.21
in general payments reported to CMS, 2019-2025
40 companies · $684 in 2025
The $684 reported for 2025 was more than what 80% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $681 · 2020: $460 · 2021: $428 · 2022: $585 · 2023: $631 · 2024: $407 · 2025: $684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,722.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $542.32 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $473.52 | 2019-2024 | |
| Astellas Pharma Global Development | $384.25 | 2023-2025 | Veozah |
| Abbvie INC. | $299.90 | 2019-2023 | Lo Loestrin Fe |
| Mayne Pharma Commercial LLC | $241.68 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $221.22 | 2019-2025 | |
| Therapeuticsmd, INC. | $220.94 | 2019-2022 | |
| Millicent US INC | $165.31 | 2020-2025 | Femlyv, Intrarosa |
| Gynesonics, INC. | $160.13 | 2022 | |
| Sumitomo Pharma America, INC. | $109.24 | 2023-2025 | Myfembree, Gemtesa |
| Baxter Healthcare | $106.39 | 2025 | Tisseel, Floseal |
| Amgen INC. | $87.25 | 2019-2021 | |
| Myovant Sciences INC. | $84.25 | 2022 | |
| Novo Nordisk INC | $81.23 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Evofem Biosciences, INC. | $63.69 | 2022-2025 | Phexxi, Solosec, Phexx |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadine Becker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.